Recently, the research findings on AAV9 pre-existing antibodies conducted jointly by Peking Union Medical College Hospital and Genecradle Therapeutics were officially published in the journal Virus Research . This study, covering 341 healthy individuals and rare disease patients in China, systematically revealed the distribution characteristics of AAV9 antibodies in the Chinese population for the first time, providing a key scientific basis for the clinical development of gene therapy.
The study found that the positivity rate of AAV9 neutralizing antibodies in the Chinese population shows a significant age difference: the positivity rate in infants aged 6 months to 3 years is only 7.7%, which is the golden window period for gene therapy; while the positivity rate in adults over 18 years old is as high as 75%. It was also confirmed that there is no significant difference in the positivity rate of AAV9 antibodies between rare disease patients and healthy individuals, indicating that antibody distribution is mainly driven by age rather than the disease state itself. This "U-shaped curve" finding provides precise guidance for the timing of gene therapy.
As an important participant in the study, Genecradle Therapeutics' pipeline layout is highly consistent with the research findings. Targeting genetic diseases that are prevalent in infants and young children, the company has developed several AAV9 gene therapies. The research data directly validate the scientific basis of the company's clinical strategy of targeting children under 2 years old. Notably, Genecradle's continuous innovation in vector engineering technology enables it to develop differentiated treatment plans for patients with different antibody levels.
Of particular note is the study's proposal of a "TAbs (total antibodies) alternative to NAbs (neutralizing antibodies) detection" strategy, which coincides with Genecradle's ongoing integrated screening and treatment program. This rapid response capability from basic research to clinical translation demonstrates the company's deep accumulation in the field of gene therapy. Faced with the challenge of high antibody positivity rates in adult patients, Genecradle, relying on its proprietary vector platform, has laid out a new generation of technical solutions. It is reported that the relevant research projects have received positive feedback from regulatory authorities in the preIND phase and are expected to break through existing technical bottlenecks, providing treatment opportunities for a broader population.
From Scientific Mapping to Healing the Future:
Advancing the Age-Integrated Development of Gene Therapy
Gene Cradle
The first "China AAV9 Antibody Map" created by this study fills the data gap and provides a basis for precisely selecting the timing of treatment. Starting from the data of the Chinese population, Genecradle has always adhered to a science-driven R&D strategy. With the deepening of research and technological breakthroughs, the company is expected to further expand the applicable population for gene therapy, benefiting more patients with innovative therapies.